🍪 The GLP Lounge uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsSide Effects & ManagementWhen to stop GLP-1 — need advice

When to stop GLP-1 — need advice

pam_stl Mon, Oct 20, 2025 at 2:04 AM 39 replies 1,952 viewsPage 1 of 8
This thread is more than 7 months old. Information may be outdated. Consider searching for more recent discussions.
pam_stl
Member
267
1,123
Oct 2024
St. Louis, MO
Oct 20, 2025 at 2:04 AM#1

The nausea I get is not really nausea, it is an aversion. Food I want in the abstract becomes repellent in front of me, which no side-effect list describes.

The question I want answered is what distinguishes the nausea you can titrate through from the nausea that means stop.

Not looking for reassurance. Looking for the part I have got wrong.

1 21Dr.ObesityMed
Reply Quote Save Share Report
RetaRick_CA
VIP Member
2,012
9,876
Jan 2024
California
Oct 20, 2025 at 2:58 AM#2

This one has a reasonably settled answer, so here it is. The practical protocol is dull and it works: smaller meals, stop eating at the first sign of fullness rather than at the end of the plate, drop the fat fraction of meals in the two days after dosing, and do not lie down straight after eating. Most of what people call unmanageable nausea is a meal-size and meal-composition problem interacting with a stomach that is emptying slowly.

Last edited: Oct 20, 2025 at 3:58 AM
50 20AmyNC_wife, SkepticalSean, Dr.CardioMD and 47 others
Reply Quote Save Share Report
DanielChem_CHI
Senior Member
1,234
5,678
Mar 2024
Chicago, IL
Oct 20, 2025 at 3:52 AM#3
RetaRick_CA said:
The practical protocol is dull and it works: smaller meals, stop eating at the first sign of fullness rather than at the end of the plate, drop the…

Agreed on adaptation, with a caveat: adaptation applies to gastric emptying and not to everything. If your problem is the aversion rather than the fullness, waiting does less, because the aversion is central and it is the mechanism working as intended.

49 19patPC_UT, Dr.DermMIA, fiona_VT and 46 others
Reply Quote Save Share Report

Janoshik Analytical — Independent Testing

Trusted third-party HPLC & mass spectrometry analysis. Verify peptide purity with the lab the community relies on. Independent. Accurate. Transparent.

Verify Your Peptides

GL Biochem (Shanghai) Ltd. — Direct Manufacturer

Est. 1998. The synthesis house behind the vials you send for testing. ISO 9001 and cGMP certified, 1,500+ staff, batch-specific COA with every order.

Browse GL Biochem
kim_atl_prep
Member
312
1,345
Aug 2024
Atlanta, GA
Oct 20, 2025 at 4:46 AM#4
pam_stl said:
The nausea I get is not really nausea, it is an aversion.

Same position here, arrived at the long way round. Holding genuinely reduces total burden rather than redistributing it, because the gastric-emptying component adapts. Receptor-level tachyphylaxis to the delayed-emptying effect develops over weeks while the central appetite effect persists, so the same dose is materially more comfortable at week six than at week two. A slower ladder therefore reaches the same dose with less cumulative nausea, not the same nausea spread thinner.

48 18SleepDoc_PDX, RegAffairsDC, BiostatsBrad and 45 others
Reply Quote Save Share Report
GenomicsKate
Member
345
1,890
Oct 2024
Cambridge, MA
Oct 20, 2025 at 9:52 AM#5

Clinical perspective, offered as context rather than as advice. If two explanations both fit, the useful question is which one predicts something the other does not. That is answerable; arguing about which sounds more plausible is not.

If somebody has the primary source to hand I would rather cite it than paraphrase it.

47 17claudia_zurich, nancy_portland, rick_sfbay and 44 others
Reply Quote Save Share Report
1238

Similar Threads

Nausea incidence by dose tier — STEP and SURMOUNT meta-analysis16 replies
Constipation on GLP-1: pathophysiology and fiber protocol5 replies
Alopecia on GLP-1 — telogen effluvium differential diagnosis3 replies
Gallbladder disease risk — cholelithiasis data from clinical trials12 replies
Pancreatitis risk assessment — pooled safety analysis15 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register